Get on the Fast-Track — the Life-Cycle Approach To
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Charting a Path Along the Continuum of PMTCT of HIV-1, to Elimination, and Finally to Eradication
EDITORIAL Charting a path along the continuum of PMTCT of HIV-1, to elimination, and finally to eradication In this editorial we traverse the continuum of We stress that much of the hard scientific data on prevention transmission of HIV-1 from mothers to children to and elimination are already available; what is required are health highlight the biomedical history of this problem. service refinements. Eradication demands many more basic science Treatment has progressed from prevention with experiments to confirm the results indicating ‘cure’ in the Mississippi antiretrovirals (ARVs) through to a broader set of baby, and to increase our understanding of the biology of latency interventions, including various breastfeeding options and other health and destruction of the replicative capacity of the virus. We need system improvements, that have increased the possibility of eliminating more information on the cellular and molecular environment of mother-to-child-transmission (MTCT) of HIV. At the far end of the the CD4+ memory cells, and specific sites that harbour the virus. continuum, the spectacular findings in the case of the Mississippi Among the prerequisites for eradication are public health studies ‘cured’ baby indicate that eradication is possible. to enable SA to scale up facilities and personnel for very early HIV infections in children are overwhelmingly due to MTCT,[1] intra- diagnosis and treatment. uterine infections accounting for 10 - 25% of cases and intrapartum infections and those through breastfeeding for 35 - 40%. High- and Prevention middle-income countries have had considerable success in preventing Numerous reviews of trials undertaken to prevent MTCT have new HIV infections in children. -
Altering Cell Death Pathways As an Approach to Cure HIV Infection
Citation: Cell Death and Disease (2013) 4, e718; doi:10.1038/cddis.2013.248 OPEN & 2013 Macmillan Publishers Limited All rights reserved 2041-4889/13 www.nature.com/cddis Review Altering cell death pathways as an approach to cure HIV infection AD Badley*,1,2, A Sainski2,3, F Wightman4,5 and SR Lewin4,5 Recent cases of successful control of human immunodeficiency virus (HIV) by bone marrow transplant in combination with suppressive antiretroviral therapy (ART) and very early initiation of ART have provided proof of concept that HIV infection might now be cured. Current efforts focusing on gene therapy, boosting HIV-specific immunity, reducing inflammation and activation of latency have all been the subject of recent excellent reviews. We now propose an additional avenue of research towards a cure for HIV: targeting HIV apoptosis regulatory pathways. The central enigma of HIV disease is that HIV infection kills most of the CD4 T cells that it infects, but those cells that are spared subsequently become a latent reservoir for HIV against which current medications are ineffective. We propose that if strategies could be devised which would favor the death of all cells which HIV infects, or if all latently infected cells that release HIV would succumb to viral-induced cytotoxicity, then these approaches combined with effective ART to prevent spreading infection, would together result in a cure for HIV. This premise is supported by observations in other viral systems where the relationship between productive infection, apoptosis resistance, and the development of latency or persistence has been established. Therefore we propose that research focused at understanding the mechanisms by which HIV induces apoptosis of infected cells, and ways that some cells escape the pro-apoptotic effects of productive HIV infection are critical to devising novel and rational approaches to cure HIV infection. -
The Importance of Community Engagement in Hiv Cure Research
tagline Vol. 26, No. 1, May 2019 SCIENTIFIC COMPLEXITY AND ETHICAL UNCERTAINTIES: THE IMPORTANCE OF COMMUNITY ENGAGEMENT IN HIV CURE RESEARCH By Richard Jefferys Introduction The past decade has seen a major expansion of the research Recent presentations at the March 2019 CROI indicate that effort to develop a cure for HIV infection. The U.S. National two additional people may have joined Brown,6,7 but follow-up Institutes of Health (NIH), the world’s largest biomedical is far shorter: One of the individuals has been off ART without research funder, has identified the pursuit of a cure as one of evidence of HIV rebound for 18 months, while the other is at five primary priorities for HIV.1 Total global financial support about four months. increased substantially in the period 2012–2017, from $88 million to $288.8 million.2 In 2014, TAG launched an online Translating to a Wider Community listing of cure-related clinical research drawn from registries (primarily ClinicalTrials.gov). The list initially contained less These additional cases of possible cures are encouraging, than 50 entries; it currently includes 98 clinical trials and 34 but the method used to achieve this outcome cannot be observational studies that are ongoing.3 Over 7,000 people used in most people with HIV, who do not require stem cell are expected to enroll in these studies. transplants for cancer (the high mortality risk associated with transplantation precludes its use outside of this setting). As with other areas of HIV research, engagement of the community of people living with HIV and their advocates is In the absence of any known safe alternatives for obtaining vital for ensuring that the conduct of cure-related studies is similarly robust depletion of HIV from the body, investigators ethical, appropriate, and responsive to community priorities. -
G HIV/AIDS & Immune Evasion Strategies the Year 1981…
Micro 320: Infectious Disease & Defense HIV/AIDS & Immune Evasion Strategiesg Wilmore Webley Dept. of Microbiology The Year 1981… Reported by MS Gottlieb, MD, HM Schanker, MD, PT Fan, MD, A Saxon, MD, JD Weisman, DO, Div of Clinical Immunology-Allergy; Dept of Medicine, UCLA School of Medicine; I Pozalski, MD, Cedars-Mt. Siani Hospital, Los Angeles; Field services Div, Epidemiology Program Office, CDC. First Encounter: Dr. Michael Gottleib http://www.pbs.org/wgbh/pages/frontline/aids/view/ What is AIDS? Acquired Immune Deficiency Syndrome • Acquired means you can get infected with it (not inherited) • Immune Deficiency means a weakness in the body's system that fights diseases. • Syndrome means a group of health problems that make up a disease. The term AIDS refers to an advanced stage of HIV infection, when the immune system has sustained substantial damage. Not everyone who has HIV infection develops AIDS http://www.pbs.org/wgbh/pages/fro ntline/aids/view/ Global Statics of HIV/AIDS Transmission of HIV “Patient Zero” and HIV Transmission Gaëtan Dugas: A Canadian who worked for Air Canada as a flight attendant Claimed to have had over 2,500 sexual partners across North America 1972 Diagnosed with Kaposi's Sarcoma in June 1980 In 1982 the CDC linked him to 9 of the first 19 cases in Los Born February 20, 1953 Angeles, 22 cases in NYC and 9 March 30, 1984 Died (aged 31) more in 8 other cities – Total of 40 Quebec City, Quebec of the first 248 cases in the U.S. Occupation Flight attendant New Model: HIV Traveled to Haiti, Then U.S. -
Download The
WHAT ABOUT CONDOMS? CONFERENCE UPDATE: T HE CROI REPORT WHY I RIDE: Ou T AND OPEN IN THE RIDE FOR AIDS CHICAGO POSITIVELY AWARE THE HIV TREATMENT JOURNAL OF TEST POSITIVE AWARE NETWORK MAY+JUNE 2015 T HE BIGGES CHANGES IN 20 YEARS ARE COMING REIn THINK NG HIV NEW APPROACHES TO TREATMENT n CHASING THE CURE n 3D animation OF HIV Client Name: GSK/Triumeq Healthcare This advertisement prepared by: Product: Triumeq Havas Worldwide Job Number: 200 Hudson Street 65013 Filename 65013_58522_M02_DTR045R0_CouchSpread_ Last Modified 1-14-2015 12:41 PM User / PrevUs- Derrick.Edwin / Aileen.Boyce Client GSK Triumeq Art Director M. Culbreth Bleed 16.25” x 10.75” Path Premedia:Volumes:Premedia:Pre- CMYK press:65013_58522:Final:Pre- 0000065013_0000058522_M02_DTR045R0_FCAD – Positively Aware New York, New York 10013 Create 1-14-2015 10:42 AM Artist Kerry Trim 16” x 10.5” press:65013_58522_M02_DTR045R0_ CouchSpread_FCAD-for PREPRESS. Proof Caption: “I have the courage to start HIV…” (Man on Couch) 3 Traffic R. Rodriguez Saftey 15” x 10” indd Fonts Helvetica Neue LT Std (75 Bold, 77 Bold Condensed, 57 Condensed, 55 Roman, 47 Light Condensed, 67 Medium Condensed, 47 Light Condensed Oblique; OpenType), Minion Pro (Regular; OpenType), TT Slug Media: 4/C Magazine Spread + PBW +PBW + ½ PBW AD: M. Culbreth OTF (Regular; OpenType) PAR # DTR045R0 AE: M. Halle Art TRIU_58522_01_CeasarCouchAd_SW_V6_HR.tif (Premedia:Prepress:65013_58522:Original:1.14.15:0000065013_0000058522_M02_DTR045R0_CouchSpread_FCAD Folder:Links:TRIU_58522_01_CeasarCouch- Ad_SW_V6_HR.tif), ViiVHCcmyk.ai (Premedia:Prepress:65013_58522:Original:1.14.15:0000065013_0000058522_M02_DTR045R0_CouchSpread_FCAD Folder:Links:ViiVHCcmyk.ai), Triumeq_US_CMYK_Reg_NEW. Prod: I. Waugh ai (Premedia:Prepress:65013_58522:Original:1.14.15:0000065013_0000058522_M02_DTR045R0_CouchSpread_FCAD Folder:Links:Triumeq_US_CMYK_Reg_NEW.ai), TRIU_58522_02_ItsTimeLogo_SW_V1_130_ B: 16.25” x 10.75” T: 16” x 10.5” Bill Studio Labor OOP to: 0000065013 S: 15” x 10” Gutter Safety = 1” B:16.25” T:16” S:15” TRIUMEQ is a once-a-day pill used to treat HIV-1. -
Study Protocol
RIVER Protocol Version 5.0 20-Oct-2016 GENERAL INFORMATION This document was constructed using the MRC CTU Protocol Template Version 3.0. The MRC CTU endorses the Standard Protocol Items: Recommendations For Interventional Trials (SPIRIT) initiative. It describes the RIVER trial, co-ordinated by the Medical Research Council (MRC) Clinical Trials Unit at UCL (herein referred to as MRC CTU), and provides information about procedures for entering participants into it. The protocol should not be used as an aide-memoire or guide for the treatment of other participants. Every care has been taken in drafting this protocol, but corrections or amendments may be necessary. These will be circulated to the registered investigators in the trial, but sites entering participants for the first time are advised to contact RIVER Co-ordinating Centre at, MRC CTU, to confirm they have the most up-to-date version. COMPLIANCE The trial will be conducted in compliance with the approved protocol, the Declaration of Helsinki 1996, the principles of Good Clinical Practice (GCP), Commission Directive 2005/28/EC with the implementation in national legislation in the UK by Statutory Instrument 2004/1031 and subsequent amendments, the UK Data Protection Act (DPA number: Z6364106), and the National Health Service (NHS) Research Governance Framework for Health and Social Care (RGF). SPONSOR Imperial College London is the trial sponsor and has delegated responsibility for the overall management of the RIVER trial to the MRC CTU (RIVER Co-ordinating Centre). Queries relating to Imperial sponsorship of this trial should be addressed to the chief investigator via the Imperial Joint Research Compliance Office. -
Where's the Cure?
A QUARTERLY JOURNAL ON HIV PREVENTION, TREATMENT AND POLITICS VOLUME 5, NO. 3 acHIeVe INSIDE Personal Perspective: CHANGING MY GENES 6 Where’s Being part of something as big as the search for the cure is a humbling experience. INCHING The TOWARD A VACCINE 9 The past two years Cure? have seen discover- ies that give hope that it may be possible to find an effective vaccine. THE FUTURE OF HIV PREVENTION 12 Three decades into the HIV epidemic, the A Look At Research number of new infections remains distress- ingly high. Across the U.S. HEPATITIS C: NEW DANGERS, that NIH granting procedures drastically NEW HOPES 16 by Stephen LeBlanc New information on slowed research and diverted money to transmission and a cure. university overhead costs, rather than to n 2009, Martin Delaney, a leading the search for a cure. Proponents esti- AIDS activist and the founder of Personal Perspective: mated a budget for the AIDS Cure Project Project Inform, co-authored an arti- MY FIGHT FOR A of $1.84 billion over five years. cle in Science calling for a new “HIV HEPATITIS C CURE 20 ICollaboratory” to focus on cure research. The Delaney Collaboratories The data on the new drug looked fabulous. The Collaboratory would be designed “to Nothing like the HIV Collaboratory or I thought, “I want this drug!” accelerate basic discovery and the clinical the AIDS Cure Project ever emerged, LOOKING BACK, translation of these discoveries.” Sadly, either in the amount of funding or in the LOOKING FOR- he died before the article was published. -
2016 Annual Report
June 12, 2017 Dear Friend of TAG: I’m so proud to share with you Treatment Action Group’s 2016 Annual Report. As you will see, TAG’s passionately dedicated, deeply informed staff have been unstinting in their efforts to speed up research and high-quality prevention, treatment, and care programs for people living with HIV, hepatitis C virus (HCV), or tuberculosis (TB), and for those most at risk of acquiring these infections. Today, more than ever, TAG’s work is vital. We are living Ending the in an unprecedented political era. Every day brings a new outrage and gathering threats to our work promoting research, prevention, and treatment. Everything TAG has fought for over the past three decades to defeat HIV/AIDS and end the TB and HCV Epidemic epidemics is at risk. Our progress towards ending these epidemics with Progress in the Fight extremely effective new tools for prevention, treatment, and cures will be in vain if people don’t have comprehensive for Better Treatment, coverage to ensure access. TAG’s vital work needs your support now more than ever: a Vaccine, and a • TAG is leading community efforts to end AIDS as an 2016 epidemic in New York State by the close of 2020 by Cure for AIDS Annual strengthening HIV, STD, and sexual health programs for Report those most affected • TAG is expanding its Ending the Epidemic work to southern states where the HIV/AIDS epidemic continues at its worst • TAG is leading efforts to build on existing law and regulation to control drug costs • TAG is leading efforts to defend key National Institutes of Health AIDS research agencies and their budgets from brutal cuts proposed by the new administration • TAG is fighting efforts to greatly weaken the U.S. -
What Will It Take to Cure HIV?
IAS–USA Topics in Antiviral Medicine Perspective What Will It Take to Cure HIV? Investigational strategies to attempt HIV cure or remission include very detectable virus during 3 years of treat- early initiation of antiretroviral therapy to limit the latent HIV reservoir and ment but exhibited viral rebound 2 preinfection vaccination. In the setting of viral suppression, strategies include weeks to 3 weeks after stopping treat- reactivation of latently infected cells (eg, through “shock” therapy with ment. Similarly, an HIV-infected baby histone deacetylase inhibitors or other agents); use of broadly neutralizing in Milan began antiretroviral treatment antibodies, therapeutic vaccines, immunotoxins, or other immune-based 12 hours after birth and had no detect- therapies to kill latently infected cells; and gene editing to induce target able virus for 3 years while receiving cell resistance (eg, by eliminating the CC chemokine receptor 5 [CCR5] treatment but exhibited viral rebound 2 coreceptor). Improved ability to detect and quantify very low levels of virus weeks to 3 weeks after stopping treat- is needed. This article summarizes a presentation by Jintanat Ananworanich, ment.5-9 MD, PhD, at the IAS–USA continuing education program held in New York, In general, it is believed that earlier New York, in October 2014. initiation of antiretroviral therapy and the longer it is maintained improve the Keywords: HIV, cure, remission, viral reservoir, latent infection chance of limiting the viral reservoir and achieving HIV remission. How- ever, among the infants who eventually HIV cure research currently focuses 7 months, respectively, after receiv- exhibited rebound after stopping anti- on 2 goals: complete eradication of ing bone marrow transplantation with retroviral therapy, time to viral rebound HIV from the body and HIV remission. -
Sharon Lewin
AIDS 2014 Key Media Coverage: HIV Cure 1 Key Media Coverage th 20 International AIDS Conference (AIDS 2014) Melbourne, Australia July 20-25, 2014 AIDS 2014 Key Media Coverage: HIV Cure 2 HIV Cure AIDS 2014. Melbourne, Australia A. Wire Reuters ............................................................................................................................................... 3 Bloomberg .......................................................................................................................................... 5 Agence France Press (AFP) .............................................................................................................. 10 Australian Associated Press (AAP) .................................................................................................. 12 Indo-Asian News Service ................................................................................................................. 13 B. Broadcast ABC RADIO ......................................................................................................................................... 18 9NEWS ............................................................................................................................................. 33 7NEWS ............................................................................................................................................. 33 C. Online media and blogs The Sydney Morning Herald ................................................................................................................. -
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection Developed by the HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—A Working Group of the Office of AIDS Research Advisory Council (OARAC) How to Cite the Pediatric Guidelines: Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at http://aidsinfo.nih.gov/content- files/lvguidelines/pediatricguidelines.pdf. Accessed (insert date) [include page numbers, table number, etc. if applicable] Use of antiretrovirals in pediatric patients is evolving rapidly. These guidelines are updated regularly to provide current information.The most recent information is available at http://aidsinfo.nih.gov. What’s New in the Pediatric Guidelines (Last updated April 14, 2020; last reviewed April 14, 2020) The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has reviewed previous versions of the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection and revised the text and references. Key updates are summarized below. April 14, 2020 When to Initiate Therapy in Antiretroviral-Naive Children • The Panel now recommends rapid initiation of antiretroviral therapy (ART) for all children, not just those aged <1 year. Rapid initiation is defined as initiating therapy immediately or within days of HIV diagnosis. • Because the Panel no longer makes recommendations about when to initiate ART based on a child’s age (either <1 year of age or ≥1 year of age), Table A has been deleted and the data that support rapid initiation have been grouped by outcome (i.e., survival and health benefits, neurodevelopmental benefits, immune benefits, and viral reservoirs and viral suppression). -
Editing a Cure
MILESTONES infection and prompted further research into gene-based therapies to genome editing target HIV. Although genome editing had had been been proven efficient in rendering proven efficient T cells refractory to HIV infection, in rendering it was not until years later, in 2014, T cells that a team led by Pablo Tebas and Carl June at the University of refractory to Pennsylvania in Philadelphia showed HIV infection this could be done in infected Credit: Bloomberg/Rob Waters via Getty Images Getty via Bloomberg/Rob Waters Credit: individuals. The clinical trial enrolled 12 patients who were infused with autologous CD4+ T cells modified at the CCR5 locus by zinc-finger nucleases (ZFNs). The patients who stopped ART after cell transfusion exhibited slow viral rebound and proliferation of the modified T cells, MILESTONE 18 indicating enhanced control of the virus. Moreover, one study participant with no viral rebound Editing a cure during ART interruption was found to harbor a single mutated copy of CCR5 and after transfusion a large Timothy Ray Brown—also known transplantation and interruption of proportion of this patient’s T cells as the ‘Berlin patient’—is the only antiretroviral therapy (ART). were resistant to HIV. person ever to be cured of HIV. His Although at the time of transplant Together, these findings story and the research that followed Brown also carried HIV variants demonstrated that gene-targeting are intimately linked to the discovery, tropic for the CXCR4 chemokine approaches could provide a safer back in 1996, that homozygosity for receptor, Hütter reasoned that their and more practical approach than a CCR5 allele with a 32-base-pair numbers might have been too low to the risky and restrictive HSCT and deletion (delta32/delta32) renders allow reseeding of the new immune opened the door for ZFNs and some individuals resistant to system.